[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Edgewise Therapeutics insider transactions by Russell Alan J: The reporting person executed transactions on 08/26/2025. The Form 4 shows an acquisition of 100,000 shares of common stock at a reported price of $0.18 and a sale of 100,000 shares at an average price of $14.5976 (range $14.40 to $14.825). After the non-derivative transactions, the reported beneficial ownership in common stock is 123,400 shares following the acquisition line and 23,400 shares following the sale line. The filing also reports ownership of derivative securities: a stock option (strike $0.18) for 100,000 shares exercisable from 06/27/2021 and expiring 06/27/2032, and a reported number of derivative-linked common shares beneficially owned of 1,247,365. The signature block shows the Form was signed by an attorney-in-fact on 08/28/2025.

Insights

Securities Analyst

TL;DR: Officer and director executed matched exercise/acquisition and sale of 100,000 shares, retaining significant derivative-linked ownership.

The filing documents a contemporaneous acquisition at a reported price of $0.18 and a sale at an average price of $14.5976 for the same nominal amount of 100,000 shares on 08/26/2025. The reporting person holds a stock option exercisable since 06/27/2021 for 100,000 shares (strike $0.18, expiring 06/27/2032) and the Form lists 1,247,365 derivative-linked shares beneficially owned. These disclosures are routine Section 16 activity by an insider who is both an officer (Chief Scientific Officer) and a director; they provide transparency on insider liquidity and continuing option-related economic exposure.

Corporate Governance Expert

TL;DR: Transactions are properly reported and signed by attorney-in-fact; ownership and option details are disclosed.

The Form 4 includes required details: transaction codes, amounts, prices (including a footnote that the sale price is an average of multiple trades between $14.40 and $14.825), and post-transaction beneficial ownership figures. The reporting person is identified as both a director and the Chief Scientific Officer. The filing appears complete for the disclosed transactions and includes an explicit offer to provide granular sale-by-sale prices on request, which supports regulatory transparency.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russell Alan J

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2025		M		100,000	A	$0.18	123,400	D
Common Stock	08/26/2025		S		100,000	D	$14.5976(1)	23,400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.18	08/26/2025		M			100,000	06/27/2021	06/27/2032	Common Stock	100,000	$0.00	1,247,365	D

Explanation of Responses:

1. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $14.40 to $14.825, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Russell Alan J	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Russell Alan J report on Edgewise Therapeutics (EWTX)?

The Form 4 shows an acquisition of 100,000 common shares at $0.18 and a sale of 100,000 common shares at an average price of $14.5976 on 08/26/2025.

How many shares does the reporting person beneficially own after these transactions?

The filing shows post-transaction reported direct common stock ownership of 123,400 shares following the acquisition line and 23,400 shares following the sale line; derivative-linked beneficial ownership is reported as 1,247,365 shares.

Does Russell Alan J hold any stock options in EWTX?

Yes. The Form reports a stock option to buy 100,000 shares with an exercise price of $0.18, exercisable from 06/27/2021 and expiring 06/27/2032.

What price range were the shares sold at according to the filing?

The sale of 100,000 shares occurred at prices ranging from $14.40 to $14.825; the Form reports an average of $14.5976 and offers to provide per-trade counts on request.

What is Russell Alan J's role at Edgewise Therapeutics?

The filer is identified as a Director and an Officer with the title Chief Scientific Officer.